Clean Science
Clean Science Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #52 of 68 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales. EBITDA margins are expected to improve over the next 2-3 years due to increased sales of higher-grade HALS and operational efficiencies.
From Clean Science's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales.
- HALS volume for the year is targeted above 3,000 metric tons, with consistent scale-up expected over next 2-3 years.
- EBITDA margins for HALS are projected to improve due to higher-grade product mix and operational efficiencies.
- Performance Chemical 2 plant commercialization expected by Q3 FY27, with revenues anticipated from Q1 FY28 after stabilization.
- Strategic collaborations (Geneus Chem, Kemin) expected to enhance revenue streams, including an incremental INR 300 crores over 4 years from Geneus tie-up.
2 more points from Clean Science's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Clean Science said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 100 crores capex invested in subsidiary Clean Fino Chem Limited; all future products and new lines to be developed here.
- Geneus Chem tie-up involves a capex of about INR 25 crores for a new plant to produce advanced HALS products, expected to start production in Q3 FY27.
- Additional capacity expansion is planned to meet increased demand from Kemin contract; the process has already started.
2 more points from Clean Science's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Clean Science said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Siddharth Sikchi stated that exports to the U.S. have been very steady despite tariff and China competition issues, indicating ongoing strong demand.
- A strategic 5-year contract with Kemin ensures assured volumes for certain key products, implying a secured portion of the order book with a significant global customer.
- The HALS business is expected to grow, with a revenue target of INR 250-300 crores for FY27, showing increasing order flow.
2 more points from Clean Science's call on order book
Create a free account to keep reading this call
Clean Science — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹299 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Clean Science's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Alufluoride (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Clean Science and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Clean Science Q1 FY27 results?
HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales. EBITDA margins are expected to improve over the next 2-3 years due to increased sales of higher-grade HALS and operational efficiencies.
What is Clean Science share price analysis?
Clean Science currently shows a below-average growth signal. The stock trades at a P/E of 37.7 with a market cap of ₹8,774 Cr. Investors should review the full earnings analysis for detailed insights.
Is Clean Science planning capital expenditure?
INR 100 crores capex invested in subsidiary Clean Fino Chem Limited; all future products and new lines to be developed here.
Keep Clean Science on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.